These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 27109433)

  • 1. Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
    Medina-Aguilar R; Marchat LA; Arechaga Ocampo E; Gariglio P; García Mena J; Villegas Sepúlveda N; Martínez Castillo M; López-Camarillo C
    Oncol Rep; 2016 Jun; 35(6):3696-704. PubMed ID: 27109433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic resveratrol-curcumin hybrid derivative inhibits mitosis progression in estrogen positive MCF-7 breast cancer cells.
    de Freitas Silva M; Coelho LF; Guirelli IM; Pereira RM; Ferreira-Silva GÁ; Graravelli GY; Horvath RO; Caixeta ES; Ionta M; Viegas C
    Toxicol In Vitro; 2018 Aug; 50():75-85. PubMed ID: 29501629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells.
    Ahmad N; Adhami VM; Afaq F; Feyes DK; Mukhtar H
    Clin Cancer Res; 2001 May; 7(5):1466-73. PubMed ID: 11350919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rational combinations of siRNAs targeting Plk1 with breast cancer drugs.
    Spänkuch B; Kurunci-Csacsko E; Kaufmann M; Strebhardt K
    Oncogene; 2007 Aug; 26(39):5793-807. PubMed ID: 17369857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells.
    Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF
    Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tanshinone IIA suppresses the progression of lung adenocarcinoma through regulating CCNA2-CDK2 complex and AURKA/PLK1 pathway.
    Li Z; Zhang Y; Zhou Y; Wang F; Yin C; Ding L; Zhang S
    Sci Rep; 2021 Dec; 11(1):23681. PubMed ID: 34880385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
    Hu K; Law JH; Fotovati A; Dunn SE
    Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissecting the phenotypes of Plk1 inhibition in cancer cells using novel kinase inhibitory chemical CBB2001.
    Lan R; Lin G; Yin F; Xu J; Zhang X; Wang J; Wang Y; Gong J; Ding YH; Yang Z; Lu F; Zhang H
    Lab Invest; 2012 Oct; 92(10):1503-14. PubMed ID: 22890557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point.
    Ergul M; Bakar-Ates F
    Anticancer Agents Med Chem; 2019; 19(15):1846-1854. PubMed ID: 31244432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
    Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
    Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia.
    Spartà AM; Bressanin D; Chiarini F; Lonetti A; Cappellini A; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Martelli AM
    Cell Cycle; 2014; 13(14):2237-47. PubMed ID: 24874015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
    Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo.
    Spänkuch B; Heim S; Kurunci-Csacsko E; Lindenau C; Yuan J; Kaufmann M; Strebhardt K
    Cancer Res; 2006 Jun; 66(11):5836-46. PubMed ID: 16740723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer.
    Maire V; Némati F; Richardson M; Vincent-Salomon A; Tesson B; Rigaill G; Gravier E; Marty-Prouvost B; De Koning L; Lang G; Gentien D; Dumont A; Barillot E; Marangoni E; Decaudin D; Roman-Roman S; Pierré A; Cruzalegui F; Depil S; Tucker GC; Dubois T
    Cancer Res; 2013 Jan; 73(2):813-23. PubMed ID: 23144294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination Treatment of Polo-Like Kinase 1 and Tankyrase-1 Inhibitors Enhances Anticancer Effect in Triple-negative Breast Cancer Cells.
    Ha GH; Kim DY; Breuer EK; Kim CK
    Anticancer Res; 2018 Mar; 38(3):1303-1310. PubMed ID: 29491053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
    Kreis NN; Louwen F; Zimmer B; Yuan J
    Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks.
    Chabalier-Taste C; Brichese L; Racca C; Canitrot Y; Calsou P; Larminat F
    Oncotarget; 2016 Jan; 7(3):2269-83. PubMed ID: 26745677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Polo-like kinase 1 during the DNA damage response is mediated through loss of Aurora A recruitment by Bora.
    Bruinsma W; Aprelia M; García-Santisteban I; Kool J; Xu YJ; Medema RH
    Oncogene; 2017 Mar; 36(13):1840-1848. PubMed ID: 27721411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines.
    Benitez DA; Pozo-Guisado E; Alvarez-Barrientos A; Fernandez-Salguero PM; Castellón EA
    J Androl; 2007; 28(2):282-93. PubMed ID: 17050787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Wang NJ; Zhao RJ; Zhou SF
    Drug Des Devel Ther; 2015; 9():487-508. PubMed ID: 25609923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.